HLS Therapeutics (OTCMKTS:HLTRF) Trading 2.2% Higher – Should You Buy?

HLS Therapeutics Inc. (OTCMKTS:HLTRFGet Free Report)’s share price rose 2.2% on Monday . The stock traded as high as $2.75 and last traded at $2.75. Approximately 202 shares were traded during mid-day trading, an increase of 0% from the average daily volume of 201 shares. The stock had previously closed at $2.69.

HLS Therapeutics Stock Up 2.2 %

The stock’s fifty day simple moving average is $2.53 and its 200-day simple moving average is $2.50.

About HLS Therapeutics

(Get Free Report)

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.

Further Reading

Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.